Literature DB >> 12775747

Critical review of complementary therapies for prostate cancer.

Simon Wilkinson1, Gerald W Chodak.   

Abstract

Despite its prominence as the most frequently diagnosed solid tumor among men in the United States, relatively little is known about the etiology of prostate cancer. Furthermore, research into treatment strategies for prostate cancer continues to lag behind research for the other most common cancers. At the same time, however, the popularity of complementary therapies among prostate cancer patients continues to grow. In this article, we provide a critical review of the most recent evidence for dietary modifications, food supplements, and herbs in prostate cancer prevention and treatment. Despite encouraging data for some of these interventions, even the strongest proponents of complementary therapy agree that only randomized controlled trials can provide sufficient evidence on which to create universal guidelines. However, such trials are highly complex and expensive, and they require lengthy follow-up. Until such trials are completed, an opportunity exists for health care professionals to improve their knowledge and understanding of the current evidence for or against complementary therapy in prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12775747     DOI: 10.1200/JCO.2003.08.083

Source DB:  PubMed          Journal:  J Clin Oncol        ISSN: 0732-183X            Impact factor:   44.544


  7 in total

1.  Complementary therapies for cancer, more good than harm?

Authors:  Edzard Ernst
Journal:  Wien Klin Wochenschr       Date:  2003-10-31       Impact factor: 1.704

2.  MD-miniRNA could be a more accurate biomarker for prostate cancer screening compared with serum prostate-specific antigen level.

Authors:  Dong Xue; Cui-Xing Zhou; Yun-Bo Shi; Hao Lu; Xiao-Zhou He
Journal:  Tumour Biol       Date:  2015-01-05

3.  Synergistic antimicrotubule therapy for prostate cancer.

Authors:  Vaishali Pannu; Prasanthi Karna; Hari Krishna Sajja; Deep Shukla; Ritu Aneja
Journal:  Biochem Pharmacol       Date:  2010-11-16       Impact factor: 5.858

4.  Attitudes to terminal patients' unorthodox therapy: Finnish doctors' responses to a case scenario.

Authors:  Heikki Hinkka; Elise Kosunen; Ulla-Kaija Lammi; Riina Metsänoja; Pirkko Kellokumpu-Lehtinen
Journal:  Support Care Cancer       Date:  2003-11-20       Impact factor: 3.603

Review 5.  Lycopene for the prevention of prostate cancer.

Authors:  Dragan Ilic; Kristian M Forbes; Craig Hassed
Journal:  Cochrane Database Syst Rev       Date:  2011-11-09

6.  A hidden cause of hypokalemic paralysis in a patient with prostate cancer.

Authors:  Chih-Jen Cheng; Yeong-Hwang Chen; Tom Chau; Shih-Hua Lin
Journal:  Support Care Cancer       Date:  2004-11       Impact factor: 3.603

Review 7.  Preparation of PCL Electrospun Fibers Loaded with Cisplatin and Their Potential Application for the Treatment of Prostate Cancer.

Authors:  Hilla Mills; Ronald Acquah; Nova Tang; Luke Cheung; Susanne Klenk; Ronald Glassen; Magali Pirson; Alain Albert; Duong Trinh Hoang; Thang Nguyen Van
Journal:  Emerg Med Int       Date:  2022-07-15       Impact factor: 1.621

  7 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.